Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.18
Previous CloseN/A
Volume90.00K
Average Volume (3M)135.67K
Market Cap
HK$167.80M
Enterprise ValueHK$111.20
Total Cash (Recent Filing)HK$212.22M
Total Debt (Recent Filing)HK$96.37M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.37%
Share Statistics
EPS (TTM)-0.03
Shares Outstanding426,000,000
10 Day Avg. Volume89,000
30 Day Avg. Volume135,666
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Balance-sheet FlexibilityLow leverage reduces balance-sheet pressure and preserves financial flexibility during periods of weak profitability. A debt-to-equity ratio of about 0.15 gives the company greater capacity to fund operations, manage volatility, and pursue opportunities without relying heavily on additional borrowing.
Strong Recent Operating And Free Cash FlowPositive operating cash flow and free cash flow provide internally generated liquidity even while reported earnings are negative. This supports ongoing operations and self-funding capacity, reducing immediate dependence on external financing and giving management more flexibility over the next several quarters.
TTM Revenue ReboundThe strong TTM revenue rebound indicates renewed top-line momentum and suggests that product demand or commercial execution improved from the weaker prior period. If sustained, better sales growth can improve operating leverage, support investment, and provide a foundation for restoring profitability.
Bears Say
Persistent Net Losses And Negative Operating ProfitRepeated net losses and negative operating profit weaken earnings quality and indicate that revenue is not currently translating into sustainable bottom-line returns. Continued losses could reduce equity over time, limit reinvestment capacity, and make future profitability dependent on a meaningful operational recovery.
Material Gross-margin CompressionA sustained reduction in gross margin would directly constrain the company’s ability to convert revenue growth into operating earnings. Weaker pricing, product mix, or higher costs can make profitability more difficult to restore and may require operational changes before sales momentum produces durable returns.
Free-cash-flow Decline And VolatilityAlthough cash flow remains positive, the year-over-year decline shows that recent cash generation may not be fully durable or consistently expanding. Continued volatility could reduce the company’s ability to self-fund growth, absorb weaker earnings, or maintain capital allocation flexibility over time.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.18 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$167.80M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 189 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H released its earnings results on Aug 25, 2026. The company reported HK$0.005 earnings per share for the quarter.
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.157 which represents an annual dividend yield of 5.37%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H reported an EPS of HK$0.005 in its last earnings report. Following the earnings report the stock price went up 1.835%.
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.86%
12-Months-Change
Fundamentals
Return on Equity
5.37%
Trailing 12-Months
Asset Growth
1.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Essex Bio-Technology
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Ab&B Bio-Tech CO., LTD. JS Class H
―